Bayer: positive results in ophthalmology with Eylea

(CercleFinance.com) - Bayer announced on Monday positive long-term results for Eylea (aflibercept), its new treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME).


According to data accumulated over a two-year period, patients treated with aflibercept 8 mg every three or four months enjoyed the same degree of efficacy as those treated with aflibercept 2 mg, but every two or three months.

Bayer says this aims to ease the burden on patients by reducing the frequency of administration of the product, which is offered as an intravitreal injection.

For the record, aflibercept in 8 mg doses has already been approved in Europe and the United States.

These findings were presented in preparation for the ARVO conference devoted to ophthalmology, to be held next week in Seattle.


Copyright (c) 2024 CercleFinance.com. All rights reserved.